LBA50 A randomized phase III study comparing cisplatin-pemetrexed (cis-pem) with carboplatin (C)-paclitaxel (P)-bevacizumab (B) in chemotherapy naïve patients (pts) with advanced KRAS mutated non-small cell lung cancer (NSCLC): NVALT22

A-M.C. Dingemans, S. Ernst, W. Mellema, S. Burgers,J. Staal-van den Brekel, L.E.L. Hendriks, T.J.N. Hiltermann, N. van Walree, K. Maas, M. Youssef-ElSoud, B. Biesma, V. van Noord, E.F.F. Smit,J.A. De Langen

Annals of Oncology(2021)

引用 0|浏览0
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要